Zirabev®

ACTIVE PRINCIPLE:
bevacizumab

INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Cervical cancer

DATE:
30/09/2019

STATUS:
Authorized

MORE INFORMATION